Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_4
1
17%
Ph phase_3
2
33%
Ph phase_2
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

NCT02771405
completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

NCT02333292
completedphase_3

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1

NCT02705534
completedphase_2

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

NCT02405013
completedphase_2

Combination Therapy for Chronic Hepatitis C Infection

NCT01805882
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02771405Phase 3

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

Completed
NCT02333292

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

Completed
NCT02705534Phase 3

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1

Completed
NCT02405013Phase 2

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

Completed
NCT01805882Phase 2

Combination Therapy for Chronic Hepatitis C Infection

Completed
NCT02768961Phase 4

Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6